16 Cervix Carcinoma

360 Cervix Cancer

49. Haie C, Pejovic MH, Chassagne D, et al. Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiother Oncol 1988; 11 : 101-12. 50. Haie-Meder C, Kramar A, Lambin P et al. Analysis of complications in a prospective randomized trial comparing two brachytherapy low dose rates in cervical carcinoma. Int J Radiat Oncol Biol Phys 1994; 29(5) : 953-60. 51. Haie-Meder C, Milka-Cabanne N, Michel G, et al. Radiotherapy after ovarian transposition. Ovarian function and fertility preservation. Int J Radiat Oncol Biol Phys 1993; 25 : 419-24. 52. Haie-Meder C, Gargouri W, Albano M, et al. Results of treatment in patients with cervical carcinoma stage IIB distal. Radiother Oncol 2000; 55 : 67. 53. Horiot JC, Pigneux J, Pourquier H. Radiotherapy alone in carcinoma of intact uterine cervix according to Fletcher guidelines: a French cooperative study of 1383 cases. Int J Radiat Oncol Biol Phys 1988; 14(4) : 605-11. 54. Horiot JC, Barillot I. Cervix. Dijon method (adapted from Fletcher method). In Pierquin B, Marinello G (eds.). A practical manual of brachytherapy . Madison, Wisconsin: Medical Physics Publishing, 1997; 187-92. 55. Houvenaeghel G, Delpero JR, Rosello R, et al. Results of a prospective study with comparison of clinical, endosonographic, computed tomography, magnetic resonance imaging and pathologic staging of advanced gynecologic carcinoma and recurrence. Surg Gynecol Obstet 1993; 177 : 231-6. 56. Hricak H, Powell CB, Yu KK, et al. Invasive cervical carcinoma: role of MR imaging in pretreatment work-up-cost minimization and diagnostic efficacy analysis. Radiology 1996; 198 : 403-9. 57. Hunter RD, Cowie VJ, Blair V, Cole MP. A clinical trial of two conceptually different radical radiotherapy treatments in stage III carcinoma of the cervix. Clin Radiol 1986; 37(1) : 23-7. 58. Hunter RD, Wong F, Moore C, et al. Bladder base dosage in patients undergoing intracavitary therapy. Radiother Oncol 1986; 7 : 189-97. 59. Hunter RD.Female Genital Tract. In Pointon (Ed.) The Radiotherapy of Malignant Disease, 2 nd edition . Berlin, Springer-Verlag, 1991; 279-308. 60. Hunter RD, Wilkinson J, Swindell (1998) Volume in intracavitary brachytherapy – as viewed from Manchester. In R Pötter (ed): ICRU 38: The basis for a revision. Brussels: ESTRO, 1998; 76-79. 61. Hunter RD. Low-dose-rate Afterloading: The Manchester System. In HW Vahrson (ed): Radiat Oncol Gynecol Cancer . Berlin, Heidelberg: Medical Radiology, Springer, 1997; 183-8. 62. Hunter RD, Davidson SE. Low dose-rate brachytherapy for treating cervix cancer: changing dose rate. In Joslin CAF, Flynn A, Hall E (eds) Principles and practice of brachytherapy using afterloading systems . Arnold, London, 2001; 343-53. 63. ICRU Report 38. Dose and volume specification for reporting intracavitary therapy in gynaecology, International Commission on Radiation Units and Measurements, Bethesda, Maryland, 1985. 64. Joslin CA, Smith CW, Mallik. The treatment of cervix cancer using high activity 60 Co sources. Br J Radiol 1972; 45 : 257-70. 65. Joslin CAF. High dose-rate brachytherapy for treating cervix cancer. In Joslin CAF, Flynn A, Hall E (eds) Principles and practice of brachytherapy using afterloading systems . Arnold, London, 2001; 354-72. 66. Kim RY, Trottia A, Wu CJ, et al. Radiation alone in the treatment of cancer of the uterine cervix: Analysis of pelvic failure and dose-response relationship. Int J Radiat Oncol Biol Phys 1989; 17 : 973-8. 67. Kovac SR, Cruikshank SH, Retto HF. Laparoscopy assisted vaginal hysterectomy. J Gynaecol Surg 1990; 6 : 185-93. 68. Kristensen GB, Karlsen F, Jenkins A, et al. Human papilloma virus has no prognostic significance in cervical carcinoma. Eur J Cancer 1996; 32A : 1349-53.